9 valent pneumococcal conjugate vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00197769)
Timeline
Indications
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 9 valent pneumococcal conjugate vaccine
- 9-valent pneumococcal conjugate vaccine
- pneumococcal conjugate vaccine v114
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01215175 | Phase 1 | Sep 1, 2009 | Merck |
| NCT00617682 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2000 | National Institute on Deafness and Other Communication Disorders (NIDCD), University of Minnesota |
| NCT00197769 | Phase 2 | Sep 1, 2000 | Public Health England |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2009 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | Government | 1 | 1 | 1 | 2000 |
| Public Health England | Government | 1 | 1 | 1 | 2000 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2000 |
4 organizations
Page 1 / 1